BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 8573711)

  • 1. Plasma changes in breast cancer patients during endocrine therapy--lipid measurements and nuclear magnetic resonance (NMR) spectroscopy.
    Engan T; Krane J; Johannessen DC; Lønning PE; Kvinnsland S
    Breast Cancer Res Treat; 1995; 36(3):287-97. PubMed ID: 8573711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'.
    Atalay G; Dirix L; Biganzoli L; Beex L; Nooij M; Cameron D; Lohrisch C; Cufer T; Lobelle JP; Mattiaci MR; Piccart M; Paridaens R
    Ann Oncol; 2004 Feb; 15(2):211-7. PubMed ID: 14760111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early changes in the 1H-NMR plasma spectrum in patients following breast surgery.
    Engan T; Krane J; Søreide JA; Bjerve KS; Kvinnsland S
    Eur J Surg Oncol; 1993 Apr; 19(2):115-22. PubMed ID: 8491314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton magnetic resonance spectroscopy of fractionated plasma lipoproteins and reconstituted plasma from healthy subjects and patients with cancer.
    Engan T; Bjerve KS; Høe AL; Krane J
    Scand J Clin Lab Invest; 1992 Sep; 52(5):393-408. PubMed ID: 1514018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.
    Markopoulos C; Polychronis A; Zobolas V; Xepapadakis G; Papadiamantis J; Koukouras D; Lappas H; Gogas H
    Breast Cancer Res Treat; 2005 Sep; 93(1):61-6. PubMed ID: 16184460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer.
    Saarto T; Blomqvist C; Ehnholm C; Taskinen MR; Elomaa I
    J Clin Oncol; 1996 Feb; 14(2):429-33. PubMed ID: 8636753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer.
    Montagnani A; Gonnelli S; Cadirni A; Caffarelli C; Del Santo K; Pieropan C; Campagna MS; Montomoli M; Petrioli R; Nuti R
    Eur J Intern Med; 2008 Dec; 19(8):592-7. PubMed ID: 19046724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamoxifen therapy in breast cancer: do apolipoprotein E genotype and menopausal state affect plasma lipid changes induced by the drug?
    Gaibar M; Fernández G; Romero-Lorca A; Novillo A; Tejerina A; Bandrés F; Fernández-Santander A
    Int J Biol Markers; 2013 Dec; 28(4):e371-6. PubMed ID: 23828408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are the effects of tamoxifen on the serum lipid profile modified by apolipoprotein E phenotypes?
    Liberopoulos E; Karabina SA; Tselepis A; Bairaktari E; Nicolaides C; Pavlidis N; Elisaf M
    Oncology; 2002; 62(2):115-20. PubMed ID: 11914596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women.
    Esteva FJ; Hortobagyi GN
    Breast; 2006 Jun; 15(3):301-12. PubMed ID: 16230014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The interaction of alcohol consumption and oral contraceptive use on lipids and lipoproteins.
    Kruszon-Moran D; Burkman RT; Kimball AW; Bachorik PS; Gold EB
    Contraception; 1988 Jan; 37(1):39-51. PubMed ID: 3365983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton nuclear magnetic resonance spectroscopy measurements of methylene and methyl line widths in plasma: significant variations with extent of breast cancer, duration of pregnancy and aging.
    Engan T; Krane J; Kvinnsland S
    NMR Biomed; 1991 Jun; 4(3):142-9. PubMed ID: 1911102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel.
    Gaspard UJ; Buret J; Gillain D; Romus MA; Lambotte R
    Contraception; 1985 Apr; 31(4):395-408. PubMed ID: 3159546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in serum lipid and lipoprotein levels in postmenopausal patients with node-positive breast cancer treated with tamoxifen.
    Vrbanec D; Reiner Z; Belev B; Plestina S
    Tumori; 1998; 84(6):687-90. PubMed ID: 10080678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of triglyceride levels on methyl and methylene envelope line widths in proton nuclear magnetic resonance spectroscopy of human plasma.
    Mims MP; Morrisett JD; Mattioli CA; Gotto AM
    N Engl J Med; 1989 Jun; 320(22):1452-7. PubMed ID: 2716796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration of long-term tamoxifen therapy modifies the plasma lipoprotein-lipid concentration and lipid transfer protein I activity in postmenopausal women with breast cancer.
    Wasan KM; Ramaswamy M; Haley J; Dunn BP
    J Pharm Sci; 1997 Jul; 86(7):876-9. PubMed ID: 9232532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The alterations of serum FGF-21 levels, metabolic and body composition in early breast cancer patients receiving adjuvant endocrine therapy.
    Akyol M; Alacacioglu A; Demir L; Kucukzeybek Y; Yildiz Y; Gumus Z; Kara M; Salman T; Varol U; Taskaynatan H; Oflazoglu U; Bayoglu V; Tarhan MO
    Cancer Biomark; 2017; 18(4):441-449. PubMed ID: 28106545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment.
    Kvinnsland S; Anker G; Dirix LY; Bonneterre J; Prove AM; Wilking N; Lobelle JP; Mariani O; di Salle E; Polli A; Massimini G
    Eur J Cancer; 2000 May; 36(8):976-82. PubMed ID: 10885600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer.
    Morales M; Santana N; Soria A; Mosquera A; Ordovás J; Nóvoa J; Betancor P; Valerón PF; Díaz-Chico B; Chirino R
    Breast Cancer Res Treat; 1996; 40(3):265-70. PubMed ID: 8883969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.